We are live on
!
Find out more
AC
Armistice Capital Portfolio holdings
AUM
$5.62B
1-Year Est. Return
36.06%
This Fund
S&P 500
This Quarter
Est. Return
+4.66%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$6.94B
AUM Growth
+$1.21B
(+21%)
Cap. Flow
+$1.03B
Cap. Flow
% of AUM
14.89%
Top 10 Holdings %
Top 10 Hldgs %
53.97%
Holding
274
New
81
Increased
95
Reduced
45
Closed
48
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$73.4M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$72M |
| 3 |
Johnson & Johnson
JNJ
|
+$64.2M |
| 4 |
Colgate-Palmolive
CL
|
+$62.8M |
| 5 |
Dentsply Sirona
XRAY
|
+$52.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pacira BioSciences
PCRX
|
+$73.1M |
| 2 |
Freshpet
FRPT
|
+$58.3M |
| 3 |
PARA
Paramount Global Class B
PARA
|
+$48M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$43.7M |
| 5 |
KYNB
Kyntra Bio
KYNB
|
+$32.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.57% |
| 2 | Consumer Staples | 5.26% |
| 3 | Consumer Discretionary | 4.88% |
| 4 | Technology | 4.62% |
| 5 | Communication Services | 2.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Royal Caribbean
RCL
$85.7B
| $1.96M | 0.03% |
+30,000
| New | +$1.98M |
|
127
Inhibikase Therapeutics
IKT
$378M
| $1.95M | 0.03% |
+493,493
| New | +$2.06M |
|
128
Genprex
GNPX
$2.24M
| $1.77M | 0.03% |
+44
| New | +$2.48M |
|
|
DMK
129
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
| $1.68M | 0.02% |
+207,143
| New | +$2.75M |
|
|
ACER
130
DELISTED
Acer Therapeutics Inc
ACER
| $1.67M | 0.02% |
+2,204,694
| New | +$4.35M |
|
131
Children's Place
PLCE
$58.9M
| $1.61M | 0.02% |
+40,000
| New | +$1.64M |
|
132
Microbot Medical
MBOT
$121M
| $1.25M | 0.02% |
600,000
-90,000
| -13% | -$266K |
|
|
FTCH
133
DELISTED
Farfetch Limited Class A Ordinary Shares
FTCH
| $1.23M | 0.02% |
250,000
-2,546,000
| -91% | -$13.8M |
|
134
GT Biopharma
GTBP
$10.9M
| $1.21M | 0.02% |
73,334
-39,666
| -35% | -$909K |
|
|
BCTXW
135
DELISTED
BriaCell Therapeutics Corp Warrant
BCTXW
| $1.11M | 0.02% |
375,001
+1
| +0% | +$3 |
|
136
iBio
IBIO
$69.1M
| $1.09M | 0.02% |
+26,282
| New | +$676K |
|
|
ENG
137
DELISTED
ENGlobal Corp
ENG
| $1.06M | 0.02% |
+277,500
| New | +$1.66M |
|
|
RDHL
138
Redhill Biopharma
RDHL
$3.53M
| $1.06M | 0.02% |
+10,400
| New | +$1.96M |
|
139
Virax Biolabs
VRAX
$2.21M
| $1.04M | 0.02% |
+6,000
| New | +$1.17M |
|
140
Acurx Pharmaceuticals
ACXP
$6.27M
| $969K | 0.01% |
14,000
-30,000
| -68% | -$2.19M |
|
141
eBay
EBAY
$48.9B
| $913K | 0.01% |
+20,588
| New | +$943K |
|
142
Conagra Brands
CAG
$7.11B
| $906K | 0.01% |
+24,131
| New | +$894K |
|
|
IVF
143
INVO Fertility Inc
IVF
$1.86M
| $882K | 0.01% |
+48
| New | +$824K |
|
144
Home Depot
HD
$349B
| $833K | 0.01% |
+2,821
| New | +$865K |
|
145
Verastem
VSTM
$519M
| $830K | 0.01% |
166,667
| – | – |
|
146
Catheter Precision
VTAK
$977K
| $762K | 0.01% |
+2,621
| New | +$1.42M |
|
|
CANF
147
Can-Fite BioPharma American Depositary Shares
CANF
$7.63M
| $756K | 0.01% |
+16,500
| New | +$1.19M |
|
|
DRCTW
148
DELISTED
Direct Digital Holdings, Inc. Warrant
DRCTW
| $675K | 0.01% |
900,001
+1
| +0% | +$1 |
|
149
SuperCom
SPCB
$65.8M
| $673K | 0.01% |
+23,369
| New | +$910K |
|
|
CUEN
150
DELISTED
Cuentas Inc. Common Stock
CUEN
| $662K | 0.01% |
+121,009
| New | +$1.11M |
|
Similar funds
CRC
RMDI
F
EW
O
DSC
ACM
PI
Armistice Capital's Q1 2023 Portfolio in Review
As of Q1 2023, Armistice Capital held 274 positions worth $6.94B, up 21% from $5.73B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Armistice Capital deployed $1.03B of net new capital in Q1 2023, opening 81 new positions and adding to 95 existing holdings. Its largest new stake was DICE Therapeutics, Inc. Common Stock: 1,376,000 shares worth $39.4M.
By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 46% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was Freshpet, an estimated $58.3M trimmed.
- Armistice Capital's largest Q1 2023 buy was DICE Therapeutics, Inc. Common Stock: 1,376,000 shares worth $39.4M.
- Armistice Capital added most to UnitedHealth in Q1 2023, an estimated $73.4M increase.
- Armistice Capital's biggest Q1 2023 reduction was Freshpet, cutting an estimated $58.3M.
- Armistice Capital fully exited Pacira BioSciences in Q1 2023, selling an estimated $73.1M.
- Armistice Capital's ten largest holdings make up 54% of its $6.94B portfolio in Q1 2023.
- Armistice Capital opened 81 new positions and closed 48 in Q1 2023.
- Armistice Capital's portfolio value rose 21% quarter-over-quarter to $6.94B.
Based on Armistice Capital's 13F filing for Q1 2023, filed 15 May 2023.